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ABSTRACT 
  
The expression of glucose transporter 4 (GLUT4), the major glucose transporter in 
skeletal muscle is increased by caffeine and regulated by myocyte enhance factor-2A 
(MEF2A) and other transcription factors (12; 22; 38; 58; 91). Previous studies have 
shown that caffeine-induced GLUT4 expression is associated with hyperacetylation of 
histones surrounding the MEF2A binding site on the Glut4 gene (101) but the histone 
acetyl-transferases (HATs) involved are unknown. The aim of this study was to 
determine whether p300, a HAT known to interact with MEF2 transcription factors, is 
involved in acetylating histones at the Glut4 gene. 
To investigate this, differentiated C2C12 myotubes were incubated with 5mM 
caffeine ± 25μM or 40μM curcumin (a potent inhibitor of p300 HAT activity). Chromatin 
Immunoprecipitation (ChIP) assays were used to measure the levels of acetylated 
histone H3 (Lys 9/14) and the amount of MEF2A that bound to the Glut4 promoter. 
Western Blotting was conducted to determine total acetyl H3, p300 and GLUT4 
contents. 
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Caffeine treatment significantly increased total acetylated H3 and p300 contents by 33% 
and 12% respectively (P<0.01 vs. control). Addition of curcumin causes a dose-
dependent decrease in caffeine-induced total acetylation and p300 content:  40µM 
curcumin significantly reduced the increase in total acetyl-H3 levels by 47% and 
reduced the rise in p300 by 43% (p<0.01 Vs Caffeine) whereas the 25µM curcumin 
treatment resulted in 27% and a 20% reduction in total acetyl histone H3 and p300 
contents, respectively, compared to the caffeine-treated group (P<0.01). At the MEF2A 
binding site on the Glut4 gene caffeine treatment caused a 30% increase in acetylation 
of histone H3 and a 48% increase in MEF2A binding (P <0.001 vs. Control) but 
curcumin attenuated both caffeine-induced hyperacetylation of histone H3 and MEF2A 
binding in a dose- dependent manner: The 40µM treatment significantly reduced 
caffeine-induced acetylation of histones by 41 % (P< 0.01vs. Caffeine) and MEF2A 
binding to the Glut4 gene by 48%; p<0.01 Vs. Caffeine) whereas the 25µM curcumin 
treatment caused a 28% reduction in acetylated H3 (P< 0.01 vs. Caffeine) and a 30% 
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reduction in MEF2A binding at the Glut4 gene. GLUT4 expression was 16% increased 
by caffeine treatment (vs. control) but Curcumin (25µM) decreased caffeine-induced up-
regulation of GLUT4 by 22%.  These results show that p300 serves an integral role in 
Glut4 gene expression in C2C12 myotubes and is responsible for acetylating histones 
at the MEF2A binding on the Glut4 gene. 
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CHAPTER ONE 
BACKGROUND, AIMS AND JUSTIFICATION OF THE STUDY 
 
1.1 Introduction 
 
Regular physical activity is recommended to patients with type II diabetes, or those 
predisposed to the disease because it increases glucose disposal capacity via 
increased transcription of the insulin-sensitive glucose transporter 4 (GLUT4) in skeletal 
muscle (54; 71). Exercise-induced increase in Glut4 transcription is due to increased 
binding of transcription factors, including GLUT4 enhancer factor (GEF) and myocyte 
enhancer factor 2 (MEF2), to their binding domains on the Glut4 gene (91). Although 
the signalling mechanisms that are responsible for increased interaction of these 
transcription factors with the Glut4 gene have not been fully elucidated, several lines of 
evidence suggest that fluctuations in cytosolic Ca2+ levels during contraction, leading to 
activation of Calcium/Calmodulin dependent protein kinases (CaMKs), play an important 
role : For example, Smith et al. (140), showed that inhibition of CaMK II activity during 
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intermittent high-intensity swimming prevents MEF2A binding to the Glut4 gene and 
prevents Glut4 transcription. A similar conclusion was drawn by Mukwevho et al. (101) ; 
they showed that treatment of C2C12 myotubes with caffeine, an agent that increases 
cytosolic Ca2+, caused a two-fold increase in the amount of MEF2A that bound to the 
Glut4 gene when compared to controls. Moreover, when CaMK II activity was inhibited 
using KN-93, this increase was abolished. Therefore, CaMK II activity seems to be a 
major signaling effector in MEF2-mediated GLUT4 upregulation.   
Increased binding of transcription factors to their respective domains on gene 
promoters depends heavily on acetylation of histones that neighbour these binding 
domains (10; 40; 42). Hyperacetylation of histones relaxes chromatin structure and 
results in improved accessibility of transcription factor binding sites. Histone 
acetyltransferases (HATs) are the enzymes that catalyse histone acetylation. 
Hypoacetylation of histones, on the other hand, results in chromatin condensation and 
inactivation of gene transcription. Hypoacetylation of histones is catylzed by enzymes 
called histone deacetylases (HDACs), which remove acetyl groups from histone tails. 
Un
ive
rsi
ty 
of 
 C
ap
e T
ow
n
3 
The activities of these opposing enzymes regulate chromatin structure and are 
regulated dynamically according to transcriptional needs (40; 42; 47; 143; 144).  
Scicchitano et al. (132) showed that when CaMK is inhibited, there is a reduction 
in the level of acetylation of histone H4 at the MEF2 binding site on Muscle Creatine 
Kinase (MCK) promoter in L6 myotubes. This hypoacetylation of histones resulted in 
lower levels of MEF2A that bound to the MCK promoter and lower MCK transcription. 
On the other hand, Smith et al. (140), showed that activation of CaMK II by exercise 
increased acetylation of histones in the vicinity of the MEF2 binding domain and MEF2A 
binding to the Glut4 promoter; resulting  in GLUT4 up-regulation. Hyperacetylation was 
also reported when CaMK II was activated by caffeine in C2C12 myotubes (101). 
Collectively, these observations indicate that there is a correlation between CaMK II 
activation, histone acetylation and gene expression.  
There are many reports which show that MEF2 binding to genes and its 
transcriptional activity is controlled by chromatin remodeling enzymes. In the inactive 
state MEF2 is repressively bound to HDACs, which keep promoter regions condensed 
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and inactive (40; 42; 92; 93; 143). When CaMK II is activated, MEF2 dissociates from 
HDACs and can then associate with HATs. One such HAT is p300, a coactivator of 
transcription with multiple roles in eukaryotic transcription (42; 81; 93; 136). p300 is 
endowed with a potent histone acetyltransferase (HAT) domain that acetylates MEF2 on 
seven different lysines along the protein to enhance its DNA binding activity (4; 83; 
115). Furthermore, being a large protein (300 KDa), it acts as a scaffold allowing many 
smaller proteins with discrete functions--such as the components of the general 
transcription machinery including TAF250, TATA-binding protein (TBP) and RNA 
polymerase II to bind and collectively induce transcription (69; 95; 154; 159).  
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1.2. Aims  
 
Although previous studies have shown that CaMK II activation by caffeine or exercise 
increases the level of acetyl H3 in the region surrounding the MEF2A binding site on the 
Glut4 gene (101; 140), the acetyltransferase(s) responsible for this effect has/have not 
been identified. As p300 is a potent HAT (9; 108) that influences MEF2 transcriptional 
activity in muscle, neurons and T-lymphocytes (4; 83; 87; 155; 160), this study was 
designed to investigate whether p300 plays a role in: a) acetylating histones that 
neighbour the MEF2 binding domain of the Glut4 promoter and  b) GLUT4 expression,  
in response to caffeine in C2C12 myotubes.  
1.3. Justification of the study 
 
Physical exercise serves as a therapeutic means of lowering blood glucose in people 
with type II diabetes or hyperglycaemia (57). The elucidation of molecular mechanisms 
and pathways by which exercise upregulates GLUT4 expression in skeletal muscle thus 
becomes vital as it might reveal the pharmaceutical targets that could be developed in 
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order to target these mechanisms and ultimately treat hyperglycaemia related sequelae. 
As chromatin remodeling enzymes have crucial roles in regulating gene expression, and 
have been found to be altered in disease states such as diabetes (121), the 
identification of the HAT(s) involved at the Glut4 gene would contribute to a better 
understanding of how exercise regulates GLUT4 expression with respect to accessibility 
of the Glut4 promoter. This may subsequently serve as a target for pharmaceutical 
therapies in treating Type II diabetes. 
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CHAPTER TWO 
LITERATURE REVIEW 
 
2.1. Synopsis 
 
This chapter is devoted to providing the relevant background information for a 
understanding of the regulation of GLUT4 expression in skeletal muscle. It provides 
scientific evidence which show that upregulation of GLUT4 by exercise or other means 
improves glucose homeostasis. This chapter also describes the transcriptional factors 
and the major enzymes that regulate GLUT4 expression, emphasizing the roles of 
myocyte enhancer factors, the histone modifying enzyme p300, and Ca2+/CaMK. The 
chapter is divided under the following topics: 
 The anti-diabetic effects of exercise : evidence that GLUT4 upregulation is 
beneficial in hyperglycaemic conditions. 
 Regulation of the Glut4 gene by the myocyte enhancer factor 2 family of 
transcription factors. 
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 Regulation of MEF2 transcriptional activity via CaMKII and AMPK-dependent 
chromatin remodeling. 
 The structure, function and regulation of p300. 
 Evidence showing that p300 interacts with MEF2 for MEF2-dependent gene 
expression. 
 Use of curcumin as an inhibitor of p300 . 
2.2. The anti-diabetic effects of exercise.   
 
Type II diabetes is defined as a lifestyle-related disease where there is elevated fasting 
blood glucose due to reduced tissue sensitivity to insulin (165). The ‘lifestyle’ 
connotation refers to a sedentary disposition or inadequate activity (113; 137) coupled 
with a high energy diet that contains excessive fat and sugar content (86; 125). Insulin 
is a hormone which mediates the rate-limiting step in the entry of D-glucose into skeletal 
muscle (72; 114). In the post-prandial state, when plasma insulin is elevated, glucose 
entry into muscle is primarily facilitated by the insulin-responsive GLUT4 (30; 31; 67). 
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GLUT4 serves as a vital component in the maintenance of euglycaemia as 70-80% of 
plasma glucose enters skeletal muscle (166), adipose tissue (56; 151; 152) and cardiac 
muscle (1) via this transporter. When circulating insulin levels are low, GLUT4 is found 
stored in intracellular vesicles and recycles very slowly between the vesicles and the 
sarcolemma (27). In fact, the steady state dynamics of GLUT4 trafficking between the 
vesicular and membrane fraction favours the intracellular localization of the transporter 
(18; 126; 152).  
In individuals with Type II diabetes, there is diminished glucose transport into 
skeletal muscle due to insulin resistance (29). Regular physical activity in the form of 
exercise improves glucose transport into muscle by an insulin-independent mechanism 
and upregulation of GLUT4 content (26; 78; 107).  
2.2.1. Exercise increases GLUT4 content in skeletal muscle. 
 
Kraniou et al. (71) exercised untrained male and female subjects for 60 minutes on a 
cycle ergometer and analysed muscle biopsies. They reported a rapid upregulation of 
both GLUT4 mRNA and protein which remained elevated 3 hours post-exercise (71).  
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On a similar note, Green et al. (45), noticed that 16 hours of intermittent cycling exercise 
which depletes muscle carbohydrate reserves also results in a rapid 28% upregulation 
of GLUT4 in vastus lateralis muscle (45). Ren et al. (123) had shown earlier that 
swimming caused a 2-fold increase in GLUT4 mRNA and a 50% increase in total 
GLUT4 content in the epitrochlearis muscle 16 hours after a prolonged session of 
exercise. Interestingly, these researchers found that on the second day of exercise, 
GLUT4 protein increased a further two-fold but GLUT4 mRNA remained unchanged. 
They concluded that the rapid increase in GLUT4 content, which seems to be controlled 
by pre-translational mechanisms, serve as an early adaptive response of muscle to 
exercise (123).  
Hughes et al. (54), investigated the effects of exercise on GLUT4 levels and 
glucose insulin action in 18 subjects with impaired glucose tolerance. In this study, 
subjects performed training at 50% and 75% of heart rate reserve for 12 weeks. Using a 
two-step hyperinsulinaemic-euglycaemic clamp, peripheral insulin action was 
determined as well as GLUT4 concentrations in skeletal muscle. They reported an 
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improved glucose tolerance in all trained subjects, along with a 60% increase in GLUT4 
content and lower plasma glucose concentrations after the 12 weeks of training (54). A 
similar finding was made by O’Gorman et al. (107), where acute and short term (7 days) 
training also caused an increase in overall GLUT4 content in vastus lateralis muscle 
and improved glucose disposal in obese type 2 diabetic participants. Interestingly, this 
group observed that the improvement in glucose homeostasis was a result of increased 
GLUT4 content and not due to changes in insulin signalling; suggesting that exercise 
affects GLUT4 expression via mechanisms that are independent of insulin (107). Christ-
Roberta et al. (26) explored this further in overweight non-diabetic and type II diabetic 
subjects and made a similar finding that exercise training did not improve insulin-
stimulated glucose disposal via activation of the insulin signalling pathway.  
These studies provide evidence that exercise increases glucose disposal in 
both non-diabetic and type II diabetic individuals through mechanisms that up-regulation 
Glut4 gene transcription. 
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2.2.2. Exercise induces GLUT4 translocation in skeletal muscle. 
 
Just a single bout of moderate exercise has been shown to augment glucose uptake 
within 15 min of exercise in normal human subjects (109) This effect is also true in the 
highly insulin-resistant obese Zucker rats. King et al. (66), noted a two-fold increase in 
membrane GLUT4 content and a four-fold increase in glucose transport in these rats 
after exercise when compared to non-exercised rats (66). This study shows that even 
when muscle is insensitive to insulin, as in the case of diabetes, there are other 
mechanisms that are sensitive to exercise that influence glucose homeostasis. Kennedy 
et al. (63) investigated whether exercise-induced translocation of GLUT4 in diabetics 
was any different to that of normal human subjects and found no statistical difference 
between groups: In diabetics, post-exercise sarcolemmal GLUT4 was increased by 74± 
20% above resting levels whereas in normal subjects there was a 71±18% increase 
after a 45-60 minute of cycle exercise at 60-70% of VO2 max. This finding shows that 
individuals with insulin resistance or diabetes respond similarly to exercise as normal 
subjects (63). 
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Experiments with transgenic mice that overexpress GLUT4 have conclusively 
demonstrated that by increasing the expression of this transporter in muscle, whole 
body glucose disposal can be improved (16; 122). Ren et al. (122) showed that in both 
fed and fasted rats, overexpression of the GLUT4 protein lowered plasma glucose. In 
GLUT4 transgenic mice, plasma glucose levels were 172±7 mg/dl and 78±7 mg/dl in 
fed and fasted rats, respectively, whereas plasma glucose was 208± 5 mg/dl in the fed 
state and 102±5 mg/dl when fasted in non-transgenic counterparts. The rate of glucose 
disposal was 70% higher in transgenic mice than non-transgenic mice (122). Brozinick 
et al. (16) performed GLUT4 over-expression studies in the db/db diabetic mice model 
and examined the effects of differential GLUT4 over-expression on glucose utilization, 
in-vitro glucose transport and GLUT4 translocation in young (10-12 week old) and old 
(28-30 week old) mice. They showed an overall improvement in glucose tolerance in 
young mice that over-expressed GLUT4 when compared to age-matched non-
transgenic counterparts. Older mice showed deterioration in glucose tolerance 
compared to younger mice but the decline was less in mice that over-expressed GLUT4 
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4-5-fold compared to mice that over-expressed GLUT4 only 2.3-fold. Glucose infusion 
rates were also increased in GLUT4 transgenic mice compared to non-transgenic 
controls (16). Ikemoto et al. (55) assessed the effect of a low-level increase in the tissue 
expression of GLUT4 on glycaemic control in mice that were fed a high fat diet. 
Expression of the GLUT4 transgene in these mice averted the impairment in glucose 
control that was seen in non-transgenic mice. This study showed that a two-fold 
increase in GLUT4 expression, although small, was enough to prevent a primary 
symptom of type II diabetes in a mouse model.  
The studies mentioned in this section provide evidence to support the notion 
that increasing GLUT4 content in skeletal muscle by exercise serves as a therapeutic 
mechanism to help those with type II diabetes control hyperglycaemia and prevent 
diabetic-related sequelae. However, many individuals living diabetes, obesity or insulin 
resistance are unable to exercise adequately. This underscores the importance of 
developing pharmaceutical agents that may target signalling pathways that are 
activated by exercise to increase GLUT4 expression and translocation.  
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2.3. Transcriptional regulation of the Glut4 gene. 
 
The Glut4 gene is subjected to complex hormonal and metabolic regulation as revealed 
by numerous studies in adipose tissue and muscle. This section of the literature review 
provides insight into the transcription factors that regulate the expression of the Glut4 
gene.   
2.3.1. Identification of MEF2 and GEF domains on the Glut4 promoter. 
 
Liu et al. (80) undertook the task of identifying the cis-DNA elements responsible for 
tissue-specific expression of GLUT4 by characterising and cloning the rat Glut4 gene. 
Multiple GLUT4 luciferase reporter deletion constructs of the gene were created and 
transiently transfected into differentiating C2C12 myotubes to determine which fragment 
of the gene conferred myotube-specific GLUT4 expression. Reporter assays revealed a 
103 base pair fragment (located between -522 to -422 [Domain II] from the 
transcriptional initiation site which was necessary for GLUT4 expression. Further 
mutagenesis of this fragment showed that it contained a sequence analogous to the 
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myocyte enhancer factor 2 (MEF2) binding site on the muscle creatine kinase (MCK) 
promoter. Liu et al. (80) also conducted Electrophoretic mobility gel shift assays (EMSA) 
which showed that MEF2 isoforms bound this region. This study concluded that the 103 
base pair fragment contained a MEF2 domain that was necessary but insufficient for 
transcriptional activation of the Glut4 gene.  
Knight et al. (68) identified another factor that was shown to co-operatively work 
with MEF2 via protein-protein interactions. This factor was named the GLUT4 enhancer 
factor (GEF) (68; 112) which was identified to bind upstream of domain II on the Glut4 
gene which they called  Domain I. Using transfection assays, Knight et al. (68), showed 
that expression of GEF or MEF2 by itself could not significantly activate GLUT4 
promoter activity. However, when expressed together, promoter activity increased 4- to 
5-fold; suggesting that GEF and MEF2 function together to activate Glut4 transcription 
in skeletal muscle.  
Exercise has been shown to increase both GEF and MEF2 binding to the Glut4 
enhancer in human skeletal muscle (91). In this study, 7 subjects performed 1 hour of 
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cycling at ~70% of VO2 peak. Muscle biopsies were then taken and assessed for DNA-
binding activities by EMSA. The results of the EMSA showed that an acute single bout 
of exercise was enough to significantly increase binding of both the MEF2A/MEF2D 
heterodimer pair and GEF to the Glut4 gene. Furthermore, exercise did not cause an 
increase in MEF2D or GEF nuclear content, however, MEF2A content was significantly 
increased as revealed by immunoblotting (91). These studies show us that the Glut4 
gene is regulated by these two transcription factors namely, GEF and MEF2, which 
respond to signals activated by exercise.  
2.3.2 The myocyte enhancer factor-2 family of transcription factors. 
 
The MEF2 group of transcription factors are a highly conserved group of DNA binding 
proteins in eukaryotes (43; 117). They belong to the MADS box (MCMI, Agamous and 
Deficiens and SRF) (116) family of transcription factors as they share a highly 
conserved 57- amino acid fragment on the N–terminal of the protein (161). MEF2 is 
highly expressed in T-lymphocytes (37; 160) neurons (37) and skeletal and cardiac 
muscle (98) where studies have shown MEF2 to be highly crucial for myogenic 
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differentiation (15). This conclusion came from studies where mutations in a single Mef2 
Drosophila gene prevented myoblast differentiation (79; 120). Further studies have also 
shown that dominant negative MEF2 mutants also prevent myoblast differentiation 
(111). Even though MEF2 proteins lack myogenic activity, their contribution to myogenic 
differentiation lies in its strength to exalt the activity of myogenic basic-helix-loop-helix 
(bHLH) proteins such as MyoD and myogenin (34) In addition to myogenesis, MEF2 
proteins are involved in cell proliferation, apoptosis, survival and are key regulators of 
adaptive programs, stress responses, muscle fibre-type switch, cardiac hypertrophy and 
remodeling of neuronal circuitry (37; 65; 134; 156; 158). 
There are four members of the MEF2 class of transcription factors namely 
MEF2A, MEF2B, MEF2C and MEF2D. These proteins are encoded by their respective 
genes: Mef2a, Mef2b, Mef2c and Mef2d, which are located on four different 
chromosomes (43; 53) These four isoforms share a high amino acid identity of more 
than 95% similarity (43). As mentioned above, MEF2 proteins have homologus DNA 
binding domains such as the N-terminal MADS box (aa 1-57), the highly conserved 
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MEF2 domain (aa 58-86) and the more divergent transactivation domain that aids in 
transcriptional activation. The MEF2 domain is of particular significance as it is this 
domain that localises DNA binding affinity and specificity as well as mediating homo-
and heterodimerization between MEF2 members (3; 36; 116; 157). At the MEF2 cis-
element [(CTA(AT)4TAG] on the Glut4 gene, MEF2A and MEF2D form a MEF2A-
MEF2D heterodimer, which has been shown by Mora and Pessin, (99) to be essential 
for hormonal GLUT4 expression. McGee et al. (91) have shown that exercise enhances 
the DNA-binding activites of both MEF2A-MEF2D heterodimer and GEF in human 
skeletal muscle thus indicating that heterodimer binding is not only in response to 
hormonal regulation but also in response to exercise. 
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2.4. Regulation of MEF2 transcriptional activity  
 
2.4.1 Interaction of MEF2 with HDACs and HATS. 
 
As with all transcription factors, MEF2 binding to its cis-element is largely determined by 
the accessibility of the chromatin structure neighbouring the binding domain (47). In a 
transcriptionally inactive scenario, MEF2 is bound to class II histone deacetylases 
(HDACs) (93; 94) In addition to binding MEF2, HDACs have another function, which is 
the inhibition of transcription by chromatin remodeling (96; 97). For MEF2 to become an 
active transcription factor, HDACs have to disassociate from MEF2, then only can 
transcription of a MEF2-dependent gene occur (93; 94). Calcium signaling in the form of 
calcium/calmodulin dependent protein kinases (CaMKs), are activated by exercise (124; 
139; 140) and are responsible for this disassociation (McGee et al. (91). MEF2 proteins 
are then free to associate with histone acetyltransferases (HATs), another chromatin 
remodeling enzyme that reverses the effect of HDACs (47; 118). These mechanisms 
are explained in this section as well as evidence, supporting the notion that this occurs 
at the Glut4 gene and other genes, are given in this section. 
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2.4.2 CaMK II-dependent chromatin remodeling at MEF2-dependent gene 
promoters. 
 
Accessibility of transcription factors to their binding sites on gene promoters is 
determined by numerous post-transcriptional modifications on proteins called histones 
surrounding the cis-elements. Structurally, eukaryotic DNA is wound around an octamer 
of highly conserved histone proteins (H2A, H2B, H3, and H4). When an octamer of 
histone proteins have 146 bp of DNA wrapped around it, it is referred to as a 
nucleosome. Nucleosomes are separated from each other via regions of linker DNA and 
serve as monomers of chromatin that function as building blocks to manage eukaryotic 
DNA into high-order chromatin fibres. The N-terminal tails of these histones, which 
protrude from the surface of the nucleosome, undergo many post-translational 
modifications such as methylation, phosphorylation, sumoylation and acetylation (10; 
73). Acetylation and deacetylation of lysine residues on the N-terminal tails of histones 
have been the most appreciated and researched post-translational modification that has 
been linked to chromatin structure and transcriptional activity (46; 47; 106). Current 
understanding of MEF2-mediated transcription, suggests that acetylation state in the 
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vicinity of the transcription factor is reversed during transcription (93; 94). MEF2 is 
repressively bound by Class II Histone Deacetylases (HDACs) such as HDAC4 and 
HDAC5. HDACs inhibit transcription by removing acetyl groups from lysine residues 
present on N-terminal tails on histones. This results in chromatin condensation and 
repressed transcriptional activity (21; 70; 96; 97). In diseases such as cancer, diabetes, 
cardiac-hypertrophy and asthma, altered HAT and HDAC activites have been implicated 
as contributors to the development of these diseases thus revealing that epigenetic 
mechanisms such as acetylation have pertinant consequences in disease states (110). 
Calcium dependent protein kinase II (CaMK II) has been identified to be a major 
activator of MEF2-dependent transcription in skeletal muscle. It is now clear that CaMK 
II activates MEF2 transcriptional activity by phosphorylation of HDAC5 on serines-259 
and -498 (7; 48; 92). These phosphorylated residues then serve as docking sites for the 
molecular chaperone protein 14-3-3, which bind HDACs to export them out of the 
nucleus (7; 48; 92). This promotes interaction between MEF2 and histone 
acetyltransferases (HATs) such as p300 or p300/CBP associated factors (118; 130). 
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Histone acetyltransferases catalyse the reverse reaction to HDACs i.e. they transfer 
acetyl groups onto lysine residues present on nucleosomal histones. This relaxes and 
opens up chromatin structure to transcriptional coactivators which is why histone 
hyperacetylation is synonymous with transcriptional activation (47). 
2.4.3. CaMK II activation causes histone 3(Lys 9/14) hyperacetylation at the 
MEF2A binding site on the Glut4 gene. 
 
Smith et al. (140), investigated the role that CaMK II activation played in MEF2A binding 
to and acetylation of histone 3 (Lys 9/14) on the Glut4 promoter and GLUT4 expression in 
rats in response to intermittent exercise. After receiving 5mg/kg of the CaMK II inhibitor, 
KN-93, rats were subjected to 5 X 17-minute bouts of swimming. Thereafter triceps 
muscles were harvested and assayed for the aforementioned parameters. A 2.2-fold 
increase in both MEF2A binding to the Glut4 promoter and acetylation of histone H3 
surrounding the MEF2A binding site on the Glut4 gene were noticed in this study, as 
well as a 1.8-fold increase in GLUT4 expression. More importantly, rats that were 
injected with KN-93 showed attenuation in MEF2A binding, histone hyperacetylation of 
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the Glut4 promoter and GLUT4 expression. This study concluded that CaMK II 
activation was necessary for histone hyperacetylation and MEF2A binding to the Glut4 
promoter in vivo (140). Mukwevho et al. (101), also explored the mechanism by which 
caffeine increased GLUT4 expression in C2C12 myotubes and tested whether these 
mechanisms were also CaMK II dependent. They used KN-93 to inhibit CaMK II and 
dantrolene to prevent Ca2+release from the sarcoplasmic reticulum. Caffeine is thought 
to activate CaMK II activity by triggering release of calcium from the sarcoplasmic 
reticulum (101; 110). The use of caffeine in these experiments were based on an earlier 
study by Ojuka et al. (110) who exposed L6 myotubes to 5mM caffeine for 3 hours daily 
for 5 days and found an increase in GLUT4 protein as well as increases in MEF2A and 
MEF2D in rat epitrochlearis muscle. The activation of CaMK II by caffeine is thought to 
lead to a sequence of cellular events in skeletal muscle that mimics exercise.  
      Mukwevho et al. (101) showed a 1.8-fold rise in GLUT4 mRNA and a 2.2-fold 
increase in MEF2A binding to the Glut4 gene when compared to controls. All 
aforementioned caffeine-induced changes were abolished by both KN-93 and 
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dantrolene treatment. They went further to show that when C2C12 myotubes were 
treated with caffeine, nuclear abundance of HDAC5 decreased. However, when KN-93- 
or dantrolene were used, myotubes showed no change in nuclear HDAC5 content when 
compared to controls suggesting that it was CaMK II activity that caused this nuclear 
exodus. This study provided evidence that CaMK II activation in C2C12 myotubes due 
to caffeine administration might increase GLUT4 content via an increase in histone 
hyperacetylation and MEF2A binding to the Glut4 gene (110). 
These studies, conducted in our lab, show that CaMK II activation leads to an 
increase in Glut4 gene activity. The histones surrounding the MEF2A binding site are 
found to be hyper-acetylated and MEF2A is found to be more bound to the Glut4 gene 
in response to CaMK II activation. These changes in response to CaMK II activation 
correlate well with the current understanding of MEF2 mediated transcription (93) which 
suggests that following HDAC5 dissociation and nuclear export, transcriptional co-
activators are recruited to MEF2 to reverse the acetylation state of histones surrounding 
the vicinity of the transcription factor (118). Conversely, Scicchitano et al. (132) have 
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shown that when CaMK is inhibited, there is a reduction in the level of acetylation of 
histone H4 at the MEF2 binding site on muscle creatine kinase (MCK) and myogenin 
promoters in Arg8-vasopression induced myogenic differentiation in L6 myotubes. 
Hypoacetylation of H4 in L6 myotubes also resulted in lower levels of MEF2A bound to 
the MCK promoter and lower MCK and myogenin content as revealed by western 
blotting (132). These studies show a positive correlation between acetylation of histones 
and binding of MEF2 to its cis-element on promoter regions and would therefore 
suggest that histone acetylation is necessary for MEF2 mediated transcription to occur. 
The identification of the HATs involved in acetylating histones at MEF2-regulated 
genes, such as the Glut4 gene, thus becomes necessary. This thesis therefore, aims to 
explore the potent HAT p300, which interacts with MEF2 at various levels in 
transcription as a possible HAT at the MEF2A binding domain on the Glut4 gene. 
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2.4.4. AMP-activated protein kinase also regulates GLUT4 expression by 
phosphorylating histone deacetylase 5. 
 
AMP-activated protein kinase (AMPK) is a phylogenetically conserved, fuel-sensing 
master switch that is present in the most primitive unicellular organisms right through 
higher evolved mammalian cells (49). It is activated by stresses that induce an increase 
in cellular concentrations of AMP relative to ATP which includes glucose deprivation, 
hypoxia, and more importantly, muscular contraction (14; 33; 50; 51). The principle 
function of APMK appears to be the generation of ATP through the stimulation of fatty 
acid oxidation and glucose transport (GLUT4 translocation) with concurrent inhibition of 
ATP-consuming pathways such as lipid/protein synthesis, cell growth and proliferation 
(17; 52; 74; 128; 133). 
AMPK is activated in skeletal muscle during exercise and can be induced in cultured 
muscle cell lines by treatment with 5-Aminoimadazole-4-carboxamide ribonucleoside 
(AICAR), an analog of adenosine, which leads to an accumulation of 5-aminoimidazole-
4-carboxamide-1--D-ribofuranosyl-51-monophosphate (ZMP). As ZMP mimics AMP, 
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AMPK is activated allosterically by the binding of ZMP to the -subunit of AMPK thus 
making it a better substrate for upstream kinases (32; 76). 
The following studies have made use of AICAR stimulation of AMPK activity in muscle 
with particular emphasis in measuring the response in GLUT4  expression : 
Zheng et al., (164), showed that a single subcutaneous injection of AICAR into the 
quadriceps of mice and rats resulted in an increase of GLUT4-mRNA 13 hours post –
administration. To determine which region of the Glut4 promoter was induced in 
response to AICAR treatment, transgenic animals mice were generated, carrying a CAT 
reporter gene driven by 1.154 bp of the human Glut4 gene. Reporter assays showed 
that AICAR induced either 1,154bp or 895 bp of the Glut4 gene but did not activate 
transcription within 730bp of the promoter. It was thus concluded that all elements 
required for AICAR-induced transcription of the Glut4 gene were located within 895bp of 
promoter. As this region of the gene contains two important regulatory domains, namely 
Domain I which binds GLUT4 enhancer factor (GEF) and a MEF2 binding site, 
electromobility shift assays (EMSA) was conducted on nuclear extracts prepared from 
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gastroceminus muscles. The results of these EMSA experiments showed an increase 
binding activity of MEF2A and/or MEF2D to oligonucleotides corresponding to MEF2 
binding site on the Glut4 gene, furthermore, an increase in GLUT4 protein in rats that 
were treated with AICAR for two weeks was also noted in this study (164). This study 
shows that there is an increase in Glut4 promoter activity in response to AICAR 
treatment and more importantly that this upregulation is related to the binding activities 
of MEF2 protein to the Glut4 gene (164). 
Ojuka et al. (110), showed that 1.0mM AICAR treatment of L6 myotubes resulted in a 
significant upregulation of GLUT4 protein (p<0.001) when compared to untreated 
controls. In this study, the addition of adenosine-9--D-arabino-furanoside (AraA) to 
AICAR treatments attenuated the upregulation of GLUT4. Ojuka et al. (110) also 
showed that AICAR treatment also upregulated both MEF2A and MEF2D protein in L6 
myotubes. This study demonstrates that AMPK activation in muscle increases GLUT4 
expression via a mechanism that is probable increases in MEF2 content. (110).  Thus 
far, the studies reviewed above show that in addition to an increased binding activty of 
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MEF2 protein to the Glut4 promoter as shown by Zheng et al. (164), Ojuka et al. (110) 
demonstrates that there in an increased concentration in transcription factor MEF2 to 
bind the Glut4 gene on response to AICAR treatment (110). 
As HDAC5 phosphorylation is only partially reduced when CaMK pathways are blocked 
(90), McGee et al. (90) aimed to determine whether AMPK could be the other kinase 
that phosphorylates HDAC5 thus promoting GLUT4 expression. Using Scriptaid, a low 
toxic HDAC inhibitor, they showed that HDAC inhibition resulted in a seven-fold 
increase ( p<0.05) in GLUT-mRNA and a nine-fold increase (p<0.05) in H3 acetylation 
without any change in nuclear abundance in HDAC5 content thus showing that the 
inhibitor does not alter HDAC localization. McGee et al. (90) also showed that HDAC5 
was indeed a direct substrate for AMPK by creating HDAC mutants that expressed a 
serine 259/498 to alanine mutation. By performing enzyme assays they demonstrated 
that AMPK was unable to phosphylate mutant HDAC5 at the aforementioned alanine 
residues but did phosphorylate wild type HDAC5 at serines 259 and 498. This was 
affirmed endogenously when myotubes were treated with AICAR for 60 min; which 
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caused a 40% increase in phospho-AMPK and a 65% and 100% increase in HDAC 
phosphorylation at serines 259 and 498 respectively. Nuclear abundance of HDAC5 
decreased significantly (p<0.05) as revealed by immunoblotting, whereas ChIP assays 
showed that a substantial decrease in HDAC5 associated with the MEF2 binding site on 
the Glut4 promoter while RT-PCR showed that AICAR induced transcription as GLUT-
mRNA was increased significantly (90). 
 
2.5. p300: a Potent Histone Acetyltransferase (HAT). 
 
2.5.1 Overview 
 
This section looks at p300, the protein that we hypothesise to have a role in acetylation 
of histones at the MEF2A binding site on the Glut4 gene. The transcriptional co-
activator, p300 was first identifed as a protein that interacted with the E1 adenovirus 
(82) The MADS/MEF2 domains of MEF2 transcription factors have been identified to 
interact directly with p300 (130). p300 also acetylates MEF2 on seven conserved lysine 
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residues along the MADS box and transactivation domains of (4; 83). Most significantly, 
p300 possesses a potent HAT domain at the core of the protein and has the ability to 
acetylate all core histones at multiple lysine residues along protruding N-terminal tails 
(9; 108). Given these abilities of p300 and the numerous interactions it has with MEF2 
transcription factors, we hypothesise that p300 is involved in regulating chromatin 
structure at the MEF2A binding site on the Glut4 gene. 
2.5.2. Structure of p300. 
 
 p300 is a large (300kDa), global metazoan, specific transcriptional co-activator with 
potent HAT activity and plays multi-decisive roles in proliferation, differentiation and 
apoptosis. Its central role is to integrate and co-ordinate multiple signals received from 
diverse extra-cellular cues so that an appropriate level of transcriptional events occur in 
response to various physiological stimuli. It shares a strikingly similar homology both 
functionally and structurally to that of CREB-binding protein (CBP), thus they are often 
referred to as p300/CBP family of transcriptional co-activators (42; 59; 136). p300 
coactivates transcription with a multitude of transcription factors, through various 
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mechanisms that aim to form a stable and efficient transcriptional complexes (20). As 
this study only aims to investigate whether the HAT domain of p300 is attributable to 
acetylating histones on the Glut4 gene, a review of studies showing the importance of 
the HAT domain of p300 is given especially with respect to MEF2-mediated 
transcription. 
                 Structurally (Fig.1), p300 consists of roughly 2400 amino acids and harbours 
typical structural motifs synonymous of transcriptional machinery (42). These include a 
centrally located bromodomain, three cysteine-histidine (CH) rich domains, and a 
centrally located HAT domain (20). The CH domains are thought to be important in 
mediating protein-protein interactions, however, recent work has revealed that within the 
CH domains lies three zinc fingers enabling these domains to mediate both protein-
protein and protein-DNA interactions. These interactions facilitate stabilisation of the 
Pre-Initiation Complex (PIC) which consists of obligatory factors such as RNA 
polymerase II, TAFII250 and TATA-Binding Protein (TBP); commonly referred to as the 
general transcription machinery (GTM) (13; 21; 89). Bromodomains are considered to 
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have dual roles at promoter regions (89). Firstly, they aid in identification of nucleosomal 
substrates for HATs thereby promoting interactions between enzymes and histones. 
Secondly, once specific histone sites are acetylated, bromodomains are recruited to 
acetylated residues on both histone and factors of the transcription apparatus thereby 
promoting stable interactions for further acetylation, resulting in an acetylation cascade 
(21; 42; 89). 
 
Figure 1. : Structure of p300/CBP indicating its major domains(20) 
Structural diagram showing the main functional domains in p300 consisiting of the CH1, CH2 and CH3 domains, the 
KIX domain and the bromodomains. This diagram also shows that both the N- and C-terminis can act as 
transcactivation domains with the HAT domain located centrally. 
 
 
 
 
 
 
CH – cysteine-histidine domains 
BR – bromodomain 
KIX- Kinase inducible domain  
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2.5.3 Functions of p300. 
 
p300 is a transcriptional integrator that possess intrinsic HAT activity and is capable of 
acetylating both histones as well as other cellular factors such as transcription factors 
(9; 83) Ogryzko et al. (109) first identified p300 to possess intrinsic histone 
acetyltransferase activity by purifying p300 that bound the E1 12S protein and then 
subjecting p300 to histone acetyltransferase assays using calf thymus histones and 
radiolabelled acetyl-CoA. These assays showed that p300 did posses HAT capabilites 
which were mapped to amino acids 1135-1810 of p300. Furthermore, they showed that 
p300 acetylated all core histones in mononucleosomes but preferentially acetylates H3 
and H4.   
Studies show that acetylation of these factors affects their activities by enhancing 
their DNA binding and transcriptional activities, interactions with other proteins, turnover 
and nuclear export (83; 89). Considering transcriptional regulation, p300/CBP proteins 
are respected as highly resourceful general transcriptional integrators. According to 
recent work they perform their duties through a cohort of mechanisms (refer to Figure 
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1.2): Firstly they serve as bridging molecules that connect the sequence-specific 
promoter binding transcription factors to the general transcription machinery (42; 136). 
This is the scenario in transcription factors that do not possess the binding domains to 
directly bind RNA polymerase II and associated factors. p300 also directs the 
congregation of other co-factor proteins into multi co-activator complexes (13). 
Secondly, p300 acts as a scaffold for such proteins; enabling an increase of the 
presence of these co-factors at local promoter regions through protein–protein and 
protein-DNA interactions (69; 154; 159).  Thirdly, p300 is a potent histone 
acetyltransferase and also has the ability to acetylate transcription factors thus resulting 
in enhanced binding capabilities and ultimately transcriptional activation. 
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Figure 2. : Mechanisms by which p300 facilitates transcriptional activation (20). 
Various mechanisms of transcriptional activation by p300. Firstly, p300 can act as a brdge connecting sequence-
specific transcriptional activators to the general transcriptional machinery. Secondly, being a large protein, p300 acts 
as a structural scaffold for the assembly of multiprotein complexes. Lastly, p300 is endowed with a potent HAT that is 
capable of acetylating histones as well as transcription factors (18). 
 
 
 
TF – Transcription factor 
NAP- Nucleosome assembly proteins 
JMY- junction meeting and regulatory 
proteins 
Ac- Acetyated histone 
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2.5.4. Is p300 activity regulated by phosphorylation? 
 
Chawla et al. (23) have shown that CaMK IV phosphorylation is necessary for CBP to 
mediate its transcriptional functions in neuronal cells. More recently and significantly, 
Yaun et al. (162) have shown that in response intermittent hypoxia in PC12 cells, p300 
is phosphorylated in vitro by CaMK II and that this phosphorylation is absolutely 
necessary for the transcriptional activity of the hypoxia-inducible factor 1(HIF-1). This 
was determined by transfecting PC12 cells with pGAL4p300, a GAL4 fusion protein 
containing full length p300 protein and a luciferase reporter construct pG5E1bLuc. 
These cells were then exposed to 120 cycles of intermittent hypoxia (IH), which 
increased p300 transcriptional activity. Further experiments showed that IH was 
mimicked when PC12 cells were co-transfected with CaMK II-290 and pGAL4p300.  
However, when KN-93 was administered, a CaMK II inhibitor,  neither p300 nor CaMK II 
was able to activate the IH response. It was also revealed that p300 was 
phosphorylated directly by CaMK II in an in vitro assay (162). These last two studies 
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provide evidence to show that there are CaMK dependent effects on p300 however, 
research into the effects of CaMK activity on p300 is still limited at this stage. 
2.5.5. Regulation of p300 by autoacetylation. 
 
There exists a highly basic autoacetylation loop within the HAT domain within p300 that 
is found to be hyperacetylayed when p300 is most active. Studies have shown that the 
catalytic activity of p300 can increase 4-10-fold when autoacetylated (149). p300 
autoacetylation occurs via an intermolecular manner of 17 lysine residues within the 
HAT domain of p300 (60; 61). This serves as a switch to regulate the HAT activity and 
ultimately the ability of p300 to fulfil its transcriptional co-activator duties. 
2.4.6. Interaction between p300 with MEF2 at various MEF2-dependent genes. 
 
Using the 3T3 cell line and a reporter construct consisting of a MEF2-binding site 
derived from rat embryonic myosin heavy chain (MHC) promoter, Sartorelli et al. (130) 
showed that co-transfection of p300 expression vector increased MEF2C trans-
activation 3-fold more than when there was no expression vector. Furthermore, using an 
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in vitro protein-protein interaction assay they showed that p300 protein interacted with 
various segments of GST-MEF2C fusion protein and concluded that the MADS box 
region of MEF2 factors was necessary and sufficient for the interaction between these 
proteins (130). Using EMSA, Slepak et al. (138) showed that p300 formed a complex 
with MEF2D but not MEF2A or MEF2C on the human skeletal actin (hSA) promoter in 
cardiac myocyte,  however when these experiments were repeated using the HeLa cell 
line, p300 and MEF2D failed to induce hSA activity. Slepak et al. (138) concluded that 
there are additional specific cell-type factors that contribute to the expression of the 
promoter and that in cardiac myocytes and that MEF2D acts as a selective channel for 
p300-dependent  activation of  transcription. 
MEF2C has been shown to acetylated by p300 both in vitro and in vivo in the C2C12 
myogenic cell line (83). This was achieved via conducting in vitro acetylation assays 
with immunoprecipitated p300 and His-thioredoxin-MEF2C fusion proteins. The 
outcomes of this experiment showed that MEF2 was indeed acetylated in vitro. To 
determine whether MEF2C was acetylated in vivo,  embryonic kidney stem cells (293T) 
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cells were transfected with overexpressed Flag-MEF2C in the presence of  labelled 
sodium [3H]-acetate and acetylation assays were conducted. MEF2C was found to be 
acetylated in vivo as well when overexpressed (83).  
In human MEF2C there are two lysine residues between amino acids 115 and 
210 (K116 and K119) and four lysines between amino acids 211 and 302 (K234, K239, 
K252 and K264). Furthermore, multiple sequence alignment revealed that the 4 lysines 
between 221 and 302 are fully conserved in MEF2A, MEF2B and MEF2D in vertebrates 
suggesting that these are general acetylation sites for p300 (83).  
The MADS box of MEF2 has also been found to acetylated at Lys 4 by p300 as 
revealed by mass spectrometry coupled with acetylation assays (4). This modification 
by p300 on MEF2 has been shown to augment MEF2 binding to the muscle creatine 
kinase (MCK) enhancer as revealed by EMSA. As the MADS box of MEF2C is highly 
conserved domain in vertebrates these results suggest, in accordance with sequence 
alignment studies of MEF2, that p300 acetylation of the MADS box of MEF2 proteins 
serve as a general mechanism in MEF2 mediated transcription.  
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To determine the effect of Lys4 acetylation on the co-activation MEF2C activity 
and p300, COS1 cells were co-transfected with wild type (wt) or mutant MEF2C, p300 
and a plasmid containing luciferase reporter activity. Results showed that the mutant 
form of MEF2 caused a reproducible 35% reduction in luciferase reporter activity 
suggesting that the Lys4 acetylation serves an integral part of the co-activation 
mechanism. To determine if p300 influences DNA binding, EMSA was carried out again 
with 32P-radiolabelled probe containing the MCK and nuclear extracts of myogenic C2C7 
cells alone and cells that contained purified p300. The results showed that p300 
presence caused an increase in endogenous binding activity and that the HAT domain 
was necessary for this effect since LysCoA, administration abolished binding (4). 
 Suggesting that Lys 4 acetylation by p300 enhances MEF2C binding capabilities 
Wei et al. (153) have showed that p300 overexpression induces cardiac hypertrophy in 
Sprague-Dawley mice. The consequences of increased p300 expression with respect to 
cardiac hypertrophy are the acetylation of p300 substrates histone H3 and MEF2. Using 
genetically manipulated mice that over-expressed p300, this study showed that p300 
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selectively targeted MEF2-containing elements as revealed by microarray analysis. 
Furthermore, p300 overexpression induced p300 HAT activity 2.4-fold and induced 
hyperacetylation of MEF2 without any changes in HDAC activity (153). A 47% increased 
in acetyl-H3 was also observed in response to p300 overexpression when compared to 
wild type mice. This study revealed that small increases in p300 expression are enough 
to induced hyperacetylation of histone H3 and hyperacetylation of MEF2 possibly at the 
seven lysine residues mapped by Ma et al. (83) and Angelelli et al. (4) .  
De Luca et al. (28) investigated the possible role that p300 plays in regulating the 
thyroid hormone receptor (TRs) and MEF2A. In addition to mapping the regions of TR 
and MEF2A that physically interacted with p300, they investigated whether these 
proteins formed a complex at the -myosin heavy chain promoter in human 
osteosarcoma (U2OS) cells. The findings of this study were that TR, MEF2 and p300 
form a ternary complex in vivo and that the N-terminus of  MEF2A (MADS box and 
MEF2 domain) binds the C-terminus of  p300 (aa 1572 -1868) (28). The findings of De 
Luca et al. (28) are relevant to our study as the Glut4 gene possesses a thyroid 
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hormone response element (TRE) in close proximity to the MEF2A binding site; it would 
be important to determine if the ternary complex exists on the Glut4 gene. 
The previous studies reveal that p300 is capable of interacting with both MEF2A 
and MEF2D. p300 also hyperacetylates MEF2C on lysine residues that are conserved 
throughout all members of the MEF2 family, which is thought to be a general 
mechanism to enhance the binding and transactivation functions of MEF2 and ultimately 
promote transcription (93) . As we have already established that MEF2A and MEF2D 
bind the Glut4 gene as a heterodimer (99), we now can see there is evidence 
supporting our hypothesis that p300 may be involved in GLUT4 transcription. To 
determine if p300 is involved in acetylating histones at the MEF2 binding site on the 
Glut4 gene, we are going to use a highly specific inhibitor of p300 HAT activity namely 
curcumin.  
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2.6. Curcumin: a p300 inhibitor. 
 
2.6.1. Overview 
 
Curcumin, which gives the yellow colour to the common Indian spice turmeric, is 
isolated from the rhizome of widely cultivated Curcuma longa plant (2). It has been used 
as a traditional medicine for thousands of years, in the treatment of various ailments 
such as inflammation, fever, the common cold, and wound-healing (5; 39; 77; 141; 141). 
It also acts as a beauty care agent and a blood purifier (62; 129). In 2005, two hundred 
and fifty-six papers were published on the various biological effects of curcumin. 
Researchers claim that curcumin serves as a ‘near-perfect starting material for drug 
discovery as curcumin was found to have antioxidant, anti-inflammatory, anti-viral, anti-
bacterial, anti-fungal, hepatoprotective, hypolipidaemic and anti-cancer activities (6; 8; 
75; 104; 105; 131; 135; 141; 150). Biochemically, curcumin has been shown to be an 
active oxygen scavenger, an inhibitor of lipid peroxidation, lipooxygenase (LOX), 
cyclooxygenase (COX) and protease inhibitor effects (11; 19; 41; 84). In summary, 
curcumin alters cellular expression profiles by modulating the activity of transcription 
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factors, kinases and enzymes. However, for the purpose of this thesis, its inhibitory 
effect on the HAT domain of p300 will be reviewed. 
 
2.6.2. Curcumin inhibits p300 HAT activity. 
 
Curcumin is a potent inhibitor of p300 in vitro and in vivo as revealed first by 
Balasubramanyan et al. (8). In this study curcumin was shown to be cell permeable and 
absolutely specific for the p300 HAT inhibition but not for p300/CBP associated factor 
(PCAF). They also revealed that curcumin binds directly to the p300 and not to the 
active site of either histone or acetyl-CoA, which may denotes that curcumin binding to 
p300 leads to a conformation change which results in a loss of binding efficiency for the 
active sites for both core histone and acetyl group. This also reveals that curcumin 
specifically and selectively targets the HAT domain of p300 rendering it incapable of 
enzymatic activity (8). 
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, 
Figure 3. : Chemical Structure of Curcumin(142). 
 
Curcumin is a bis-α,β-unsaturated β-diketone and undergoes keto-enol 
tautomerisation in equilibrium according to certain pH environments (85). The diketone 
is of particular significance as it has been revealed by Marcu et al. (88), to covalently 
bind the HAT domain of p300 in a sequence of addition reactions, known as the Michael 
reaction. When these carbonyls become saturated as in the case of tetrahydrocurcumin 
(THC), a hydrated form of curcumin, there are no p300 inhibitory effects. Furthermore, 
curcumin is highly selective for p300 and promotes proteosome dependent degradation 
of p300 without affecting PCAF or GCN5 (8). Curcumin is also capable of inhibitng the 
HAT activity of p300 in in vitro acetylation assays when either p53 or histone 3 are used 
Diketone 
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as substrates Marcu et al. (88). This study has also shown that curcumin inhibition of 
p300 activity can effectively blocked histone hyperacetylation induced by the HDAC 
inhibitor MS275 in PC3-M prostate cancer cells and in peripheral blood lymphocytes 
(88). 
 
2.6.3. Studies that have used curcumin as a specific inhibitor of p300 
 
To determine the effect of curcumin on histone acetylation and p300 with respect to 
nuclear factor B (NF-B) induced proinflammatory secretion under hyperglyaemic 
conditions in human monocytic THP-1 cells. Yun et al. (163), used the Enzyme-Linked 
Immunosorbent Assay (ELISA), to show that curcumin treatment significantly decreased 
total acetylation levels in a dose dependent manner. Furthermore, western blotting for 
p300 content on 1.5M curcumin-treated nuclear lysates from THP-1 cells showed that 
curcumin treatment also decreased total nuclear p300 content (163). Similarly, curcumin 
was found to prevent diabetes-associated abnormalities in kidneys of STZ-induced 
Sprague-Dawley rats by inhibiting (NF-B) association with p300 (25). In this study rats 
Un
ive
rsi
ty 
of 
 C
ap
e T
ow
n
49 
were treated first injected with STZ to induces diabetes and subsequently treated with 
curcumin for one month. Using real-time reverse transcriptase polymerase chain 
reaction (RT-PCR) and immunohistochemical analyses of rat kidneys, the results of this 
study showed that curcumin treated rats had significantly lower p300 mRNA and protein 
expression levels (p <0.05) (25). 
Curcumin was shown to repress the activity of NF-B by inhibiting p300 in 
lymphoblastic Raji cells, however in this study Chen et al. (24), showed that co-
treatment of these cells with curcumin and the proteosome degradation inhibitor, MG-
132, prevented curcumin dependent degradation of p300 as shown by western blotting. 
This study reinforces that the mechanism by which curcumin inhibits p300 is via a 
proteosome dependent degradation pathway and that p300 inhibition by curcumin can 
be reversed by the administeration of MG-132 (24).  
In human umbilical vein endothelial cells (HUVECs), Chen et al., (23) provided 
evidence that curcumin  treatment significantly reduced glucose induced upregulation of 
p300 protein, mRNA expression and total acetylated H3 via RT-PCR and westen 
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blotting (23). Teiten et al. (148) have also used curcumin as an inhibitor to determine 
whether it would affect p300 dependent proliferation of prostate cancer cells through the 
Wingless (Wnt/-catenin) signaling pathway. Results from these experiments displayed 
that 50M curcumin treatment significantly (p<0.01) abolished both p300 and CBP 
content in 22rv1 prostate cancer cells (148). Ryu et al. (127) also determined the 
inhibitory effects of curcumin on p300 on Wnt/-catenin signaling pathway but more 
importantly investigated the differential effects of curcumin analogs demethoxycurcumin 
(DMC), bisdemethoxycurcumin (BDMC) and tetrahydroxycurcumin (THC) on inhibition 
of  p300, an inducer of the (Wnt/-catenin) signaling pathway in HEK293 cells. The 
results of these experiments showed that DMC and BDMC substantially reduced p300 
levels in a dose dependent manner while THC did not affect p300 expression as 
revealed by western blotting. These results suggest that the centrally located carbonyls 
of curcuminoids are essential in reducing p300 levels, which is a finding that is in 
accordance with previous studies (88; 127). 
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As Wei et al. (153) showed that p300 overexpression induced cardiac hypertrophy, 
Morimoto et al. (100), have shown that curcumin supresses p300-induced hypertrophic 
responses in cardiomyocytes such as -MHC promoter activity and acetylated histone 3 
and 4 and p300 content. Experiments by Sun et al. (146) showed that p300 interacts 
with Mef2c, GATA4 and Nkx2.5 genes and hyper-acetylated histones at the promoter 
region of these genes in neonatal mouse cardiac myocytes. However when 30µM 
curcumin was administered to the myocytes for 24 hours, global acetylation of histone 
H3 was reduced 0.3983-fold compared to untreated controls (P <0.05). A significant 
decrease in the acetylation of H3 at promoter regions of GATA4, mef2C and Nkx2.5 
genes were observed along with subsequent significant reductions in their expression 
(146). A similar finding was observed by Sunagawa et al. (147); they showed that 
curcumin (50 mg.kg-1.day-1) inhibited p300 expression in male Sprague-Dawley rats. 
On a similar theme, Feng et al. (35) investigated the role that p300 plays in 
diabetes-induced cardiomyocte hypertrophy. Cardiomyocytes isolated from newborn 
Harlan Sprague-Dawley rats were exposed to 25mM glucose and curcumin for 48hours 
Un
ive
rsi
ty 
of 
 C
ap
e T
ow
n
52 
to determine the effects of p300 inhibition of MEF2A, MEF2C and several other 
physiological markers of maladaptive hypertrophy. They showed that curcumin, in 
addition to significantly decreasing p300 levels also prevented glucose-induced up-
regulation of MEF2A and MEF2C mRNA and protein levels. This study also showed that 
p300 inhibition also affects total MEF2A expression which is a novel finding. A possible 
explanation for this could be due to the fact that MEF2 can autoregulate its own 
expression (119) and as MEF2 interacts with p300 (130; 138) for its transcription of 
many genes in skeletal, it is highly possible that MEF2 recruits p300 for its own 
expression.  
These studies have collectively shown that curcumin is a specific inhibitor of 
p300 HAT activity in multiple cell lines and subsequently affects p300 mediated gene 
expression. It is for this reason that curcumin was chosen to investigate the potential 
role p300 might play at the Glut4 gene. 
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CHAPTER THREE 
 
DESCRIPTION OF EXPERIMENTAL PROCEDURES 
 
 
3.1. Introduction 
 
This study aimed to determine whether p300, a highly expressed histone 
acetyltransferase (HAT) in muscle, is involved in acetylating histones at the MEF2 
binding site on the Glut4 gene in response to caffeine in C2C12 myotubes. The C2C12 
myogenic cell line was chosen for this study as it serves as an appropriate model for the 
investigation of biochemical and molecular events that occur with respect to CaMK II 
activation and Glut4 transcription when treated with 5mM caffeine (44; 101; 110). Our 
approach to answer this question involved the use of Curcumin, a highly specific 
inhibitor of p300 HAT activity.  
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3.2. General tissue culture protocol 
 
C2C12 myoblasts were cultured in Dulbecco’s minimum essential medium DMEM 
containing 5mM glucose and maintained at 37ºC in 5% CO2. DMEM was supplemented 
with 10mM creatine, 100μU/ml streptomycin, 100μMU/ml penicillin, 0.25μg/ml penstrep 
fungizone (Highveld) and 10% heat-inactivated foetal calf serum (FCS) (Highveld). 
Culture medium was changed every second day and cells were washed with 10ml 
phosphate buffered saline (PBS). Sub-confluent cultures were passaged via 
trypsinisation with 0.25% trypsin-EDTA (Sigma) when myoblasts reached 60% 
confluency  and reseeded in 10cm3 Petri dishes (Greiner Bio-one). For the experiments, 
cultures were grown to 80% confluency and then differentiated for 8-13 days by 
replacing FBS with 2% horse serum (HS) (Sigma). These cells were also washed every 
second day with 10ml PBS. After cells were fully differentiated, i.e. when nearly all 
myoblasts were fused to form myotubes, treatments with caffeine and curcumin 
commenced.  
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3.3. Treatment groups 
 
 Both caffeine (Sigma) and curcumin (Sigma) were used in this study to address the 
aims of the study, which was to determine whether p300 was involved in acetylating 
histones at the MEF2A binding site on the Glut4 gene. Previously, Mukwevho et al. 
(101) had shown that caffeine treatment of C2C12 myotubes upregulated total GLUT4 
expression via hyperacetylation of H3 (Lys 9/14) and increased MEF2A binding to the 
Glut4 promoter via CaMK II-dependent mechanisms. To determine whether p300 was 
involved in these effects curcumin was added to the medium to inhibit p300 activity. 
Two doses of curcumin i.e., 40μM (Higher dose) that has been shown to effectively 
inhibit p300 HAT activity, (8) and 25μM curcumin  (Lower dose) were administered to 
C2C12 myotubes to determine if there were dose-dependent effects. In total there were 
four different treatment groups:  
a) Control (Con) group that received neither caffeine nor curcumin.  
b) Caffeine (Caf) group that received 5mM caffeine only. 
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c) Caffeine plus high dose curcumin (Caf+Cur40) that received 5mM caffeine and  40µM 
curcumin and  
d) Caffeine plus low dose curcumin (Caf+Cur 25) that received 5 mM caffeine and 25µM 
curcumin.  
      Curcumin was dissolved in dimethyl sulphoxide (DSMO), due to its poor solubility in 
water, to a stock concentration of 100mM. The appropriate concentrations of curcumin 
needed, i.e. 40M and 25M, were prepared by serial dilution and added to the 
respective culture dishes containing fully differentiated C2C12 myotubes. The final 
concentration of DMSO (Highveld) was less than 0.01% in culture dishes. Caffeine was 
prepared by dissoultion in deionized water to a stock concentration of 100mM. The 
parameters measured in this study were: global (total) acetylated H3 (Lys 9/14) and p300 
contents, GLUT4 content by western blot; acetylated and total histone H3 in the vicinity 
of the MEF2 binding site on the glut4 gene, and glut4-bound MEF2A by the Chromatin 
Immunprecipitation (ChIP) Assay. 
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3.4.Description of treatments :  
 
For determination of global (total) acetylated H3 (Lys 9/14) and p300 contents, acetylated 
and total histone H3 in the vicinity of the MEF2 binding site on the Glut4 gene, and 
glut4-bound MEF2A cells were treated with caffeine ± curcumin once whereas for 
assessment of GLUT4 expression, cells were treated with caffeine ± curcumin for 5 
days. These treatments are described below: 
3.4.1. Acute treatments : 
 
a) Control Group : Myotubes in the control group were treated with DMSO to a final 
concentration of 0.01%.  This was achieved by addition of 10L of DMSO directly to 10 
ml of culture medium and incubation for 7 hours before harvesting. 
b) 5mM Caffeine Group : Caffeine treated cells were also treated with DMSO to a final 
concentration of 0.01%. However, after one hour 500L of 100mM caffeine was added 
to 9500L of culture medium in 15ml tubes and added to petri dishes containing 
myotubes and incubated for two hours at 37C. Cells were then washed with sterile 
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PBS and replenished with media containing 0.01% DMSO until harvest four hours later. 
This was done because hyperacetylation of histones at the Glut4 promoter had been 
shown to occur ~4 hours after caffeine administration (101).  
c) Caffeine + Curcumin Groups : In these groups, myotubes were first incubated in 
media containing 40M or 25M curcumin for one hour. Medium was removed and 
fresh curcumin and 500 µl of 100mM caffeine stock solution added to culture dishes. 
Myotubes were exposed to the fresh medium containing 5mM caffeine for two hours 
before they were washed with sterile PBS. Media containing 40M or 25M curcumin 
was re-introduced to the culture dishes and incubated for a further 4 hours. Note: 
Repetative administration of fresh curcumin was needed because curcumin is 
metabolized very quickly to metabolites that are ineffective inhibitors of p300 (142). 
Therefore, in order to achieve an effective concentration within cells, repetitive doses of 
curcumin are necessary.  
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3.4.2. Chronic treatment for assessment of GLUT4 content.  
 
Chronic treatment of myotubes with 5 mM caffeine does not increase GLUT4 content 
substantially but intermittent treatments over multiple days do (110). Therefore, for 
assessment of the effects of caffeine ± curcumin on GLUT4 expression treatments were 
carried out for 3 hours per day for 5 days.  
3.5. Measurement of protein contents. 
 
After treatments, the cells were harvested, homogenized and analysed by Western blot. 
GLUT4, α tubulin, p300, total acetyl H3 and total H3 contents were assayed. 
3.5.1. Harvesting of crude protein extracts and determination of protein 
concentrations. 
 
After cell treatments were correctly performed, myotubes were washed twice with cold 
PBS containing complete protease inhibitors (Roche) at a 1X concentration. Myotubes 
were then scraped loose from the plates in 300μL of homogenising buffer (10mM Tris-
HCl, 1mM EDTA, 5mM MgCl21.4M sucrose, 10mM Na4P2O7, 20mM NaF, 0.15μM 
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Okadiac acid, 8mM Na3VO4, 1X complete protease inhibitors, 10mM NaBu), and 
aliquoted into tubes. Cells were then lysed on ice for 10 minutes and then sonicated for 
10s at 33% output.The protein concentrations of the crude extracts were determined 
using the Bradford Assay:  Five microlitres of protein sample were aliquoted into 1ml of 
Bradford reagent (0.02% Coomassie brilliant blue G250; 4.75% ethanol; 8.5% 
phosphoric acid) for 5 minutes and the absorbance was then read at 595nm using a 
spectrophotometer. Concentrations of the unknown protein samples were determined 
from a standard curve generated using a series of standard solutions of bovine serum 
albumen (BSA) (Sigma). 
3.5.2. Western blotting. 
 
 The crude protein extracts described above were solubilised in Laemmli sample  buffer 
(LSB) (250mM Tris-HCl, pH 6.8; 2% SDS, 10% glycerol; 0.01% bromophenol blue, 
50mM dithiothreitol [DTT]), incubated at 95C for 10 minutes and used immediately for 
western blotting. Protein samples were not heated for GLUT4 western blots, as per 
specifications from manufacturers (Abcam). Approximately 30µg of each protein sample 
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as well as 5µL of standard protein ladder (Colourburst, Sigma) was resolved by sodium 
dodecyl sulphate–poly acrylamide gel electrophoresis (SDS-PAGE). The appropriate 
acrylamide (Sigma) gel concentrations were used to resolve proteins were performed in 
accordance with their molecular weight i.e. a 15% gel for Acetyl H3 (17 KDa) blots, a 
6.25% gel for p300 (300 KDa) blots and a 10% gel for GLUT4 blots (45 KDa). A quantity 
of sample protein was loaded into each gel as determined by the Bradford Assay. 
Electrophoresis was conducted using the Biorad SDS PAGE apparatus at 100V for 1.5 
hours in buffer (25mM Tris, 192mM Glycine, 0.1% SDS). Proteins were then transferred 
to a polyvinylidene diflouride (PVDF) membrane (Hybond) using a BioRad transfer 
apparatus overnight at 30V at 4ºC in 1 x Transfer Buffer (25mM Tris-HCl; 192mM 
glycine; and 15% methanol). Following overnight transfer ( 8- 12 hours), membranes 
were briefly rinsed in 1 x Tris-buffered saline containing 0.1% Tween 20 (TBST) and 
then blocked with TBST containing 5% non-fat dry milk (NFDM) for 1 hour at room 
temperature. Membranes were rinsed in TBST again for incubation with the appropriate 
primary antibody. Antibodies that were included : Anti-Acetyl H3 Lys 9/14 (Cat.No.9677, 
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Cell Signalling), Anti-p300 (Santa Cruz Cat. No. sc-585), anti- GLUT4 (Abcam Cat.No. 
ab35826), alpha tubulin (Abcam Cat.No. ab4094), anti MEF2a ( Abcam Cat.No. 32866 ) 
and Histone H3 (Cat.No.9715, Cell Signaling). All antibody titres were diluted 1:1000 in 
TBST and all incubations with primary antibodies were carried out overnight at 4º C with 
rotation.  
           Following primary incubation, membranes were washed three times for 3 x 5 
minutes in TBST and then incubated with a HRP-conjugated secondary antibody (anti-
Rabbit polyclonal, Thermo-Scientific), also diluted 1 :1000 in TBST for one hour at room 
temperature with rotation. Membranes were then washed a second time (3 x 5 minutes) 
and then incubated in enhanced chemiluminescence (ECL) detection solution 
(Amersham) for 5 minutes. These membranes were then exposed to radiographic film 
for 1-5 minutes and the films developed using photographic developing and fixing 
solutions. Films containing developed bands were subsequently scanned using a 
scanner. Band intensities were quantified using UN-SCAN-IT gel 6.1 software (Silk 
Scientific). These intensities which were indicative of respective protein levels between 
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treatments, and were normalised to α-tubulin or histone H3 expressed relative to the 
control treatment in each blot. 
3.5.3. Stripping of PVDF membranes. 
 
 Membranes that had been used previously were stripped in order to normalise data. 
These membranes were washed in TBST briefly and then incubated in Stripping Buffer 
(0.5M Tris HCl, pH 6.8, 10% SDS, 0.8% β-mercaptoethanol) at 55C for 35 minutes. 
Membranes were then rinsed in deionised water, then TBST, blocked with TBST 
containing 5% non fat dry milk (NFDM)  and re-probed for α-tubulin or histone H3 
according to the western blotting protocol given above. 
3.6. Chromatin immunoprecipitation assay.  
 
The Chromatin Immunoprecipitation assay (ChIP) was used to assess the binding of 
MEF2A to the GLUT4 promoter and the degree of acetylation of histone 3 (Lys 9/14) 
surrounding the MEF2A binding site.  
3.6.1. Formaldehyde fixing and sonication. 
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 Following treatments C2C12 myotubes were cross-linked for 10 minutes by adding 
270l of 37% formaldehyde to the culture medium to give a final concentration of 1%. 
Cross-linking was inhibited by adding glycine (Sigma) to a concentration of 0.125M for 5 
minutes. Cells were then washed twice with cold PBS containing 1 X complete protease 
inhibitors and 10mM NaBu, and then scraped loose from culture dishes and aliquoted 
into polypropylene tubes (Eppendorf). Samples were the centrifuged at 5000 x g for 5 
minutes at 4C which allowed the cells to pellet. The supernatant was then removed, 
and the pellet was reconstituted in 270l SDS lysis buffer (1 % SDS, 10mM EDTA, 
50mM Tris, pH 8.1 and 1 x complete protease cocktail) and subsequently lysed on ice 
for 5 minutes.  
Sonication was then carried out to shear chromatin to fragments ~ 300-1,000bp 
using a Virsonic 60 sonicator (Virtis) set at 33% of maximal power. To achieve these 
fragment lengths, samples were sonicated for 12 bursts for 15 seconds with 60 seconds 
of rest between bursts to prevent overheating. Figure 3.1A shows that 12 bursts of 
sonication was indeed effective to produce shearing needed for immunoprecipitation 
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whereas 15 bursts produced shearing lengths of mostly 500kb and less. Samples were 
then centrifuged at 13 000 x g for 10 minutes at 4C to pellet debris. The protein 
concentration of the supernatants were determined by the Bradford Assay (Section 
3.2.2). 
 
Figure 4 : Agarose gels showing chromatin shearing for the ChIP assay. 
C2C12 myotubes were cross-linked for 10 minutes with 37% formaldehyde, then lysed in SDS lysis buffer 
and sonicated for 12 bursts for 15s seconds (A) or 15 bursts (B) with 33% maximun sonication intensity. 
Chromatin was then de-crosslinked and electrophoresed 100V for 45 minutes on a 1% agarose gel and 
stained using SYBR® Gold 
Un
ive
rsi
ty 
of 
 C
ap
e T
ow
n
66 
 
 
3.6.2. Immunoprecipitation, de-crosslinking and DNA purification.  
 
The ChIP kit (Millipore) was used for this procedure. After determining the protein 
concentrations of the sonicated cell lysates, it was calculated that 200µg of crosslinked 
protein/DNA sample would be sufficient for immunoprecipitation.  This 200µg sample 
was diluted 10-fold in ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2mM 
EDTA, 16.7mM Tris HCl, pH 8.1 and 167mM NaCl) and pre-cleared of any endogenous 
immunoglobulins by addition of 40µl (~80µg) of salmon sperm DNA/ protein A agarose  
beads (Millipore) for 1 hour at 4ºC. After this pre-clearing step, agarose was pelleted by 
centrifugation at 1000 x g for 1 minute. The supernatant, known as “input sample” (IN) 
was saved. Forty microliters of input sample was subjected to immunoprecipitation by 
incubation with an antibody against MEF2A (Abcam) (6µl) or acetylated histone H3 
antibody (Cell Signalling) (6µl), that targets Lys 9 and Lys 14, for 36 hours at 4ºC. To 
control for non specific binding, parallel ChIP experiments were conducted using an 
anti-rabbit immunoglobulin G (IgG), agarose beads only (no antibody). 
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Following the antibody incubation period, immune complexes were precipitated 
with 40µl (80µg) of salmon sperm DNA/ protein A agarose beads for 2 hours at 4 ºC. 
The complexes were then allowed to pellet by centrifugation (1000 x g for 1 minute) and 
subsequently washed with a range of kit buffers for 2 minutes at 4ºC. These buffers 
included low salt wash buffer ( 0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20mM Tris-
HCl pH 8.0, 150mM NaCl), high salt wash buffer (0.1% SDS, 1% Triton X-100, 2mM 
EDTA, 20mM Tris-HCl pH 8.0, 500mM NaCl), lithium chloride wash buffer (250mM LiCl, 
1% NP-40, 1% sodium deoxycholate, 1mM EDTA, 10mM Tris-HCl, pH 8.0) and two 
washes with TE buffer ( 10mM Tris-HCl pH 8.1, 1mM EDTA).  The washing involved the 
addition of 1 ml of each buffer to the agarose pellet, a brief incubation in the buffer (1 -2 
minutes) with rotation at 4ºC followed by centrifugation (1000 x g for 1 minute at ) in 
preparation for incubation with the next buffer. Washes with TE buffer were done at 
room temperature prior to elution of the immune complexes from the agarose beads 
with 150µl elution buffer (1% SDS, 100mM NaHCO3) for 15 minutes also at room 
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temperature. This elution procedure was done twice to make a final “immunoprecipitate’ 
(IP) volume of 300µl. 
Both Inputs (INs) and IPs were then de-crosslinked by incubation with 0.3M NaCl 
at 65ºC in a heating block for 6 hours. The protein portion was of the DNA/protein 
complex was then digested with proteinase K, (Sigma) (10µ/µl) for 1 hour at 45ºC. DNA 
was then purified using a DNA purification kit (Qiagen). Either 3500µl or 250µl of 
Binding Buffer was added to the IP or IN respectively. Ten µl of 0.3M sodium acetate 
was then added to the sample to adjust the pH (7.4) so that it would be most effective 
for DNA binding. Samples were then added to a spin column (Qiagen), that contained a 
filter that binds DNA (via a process of adsorption) and centrifuged at 13 000 rpm for 1 
minute at room temperature. The column was then washed with 750µL of Wash Buffer 
(70% ethanol) and centrifuged at 13 000 rpm for 1 minute. DNA was eluted by addition 
of 30µl of deionised water to the column, and allowed to incubate for 5 minute at room 
temperature. DNA was collected via centrifugation of the column at 13 000 rpm for 1 
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minute. DNA concentrations and purity was calculated by spectrophotometry at 260nm 
using a quartz cuvette.  
3.6.3. Polymerase Chain Reaction and agarose gel electrophoresis. 
 
Five µl of DNA from both Input and corresponding Immunoprecipitate sample was 
amplified using the polymerase chain reaction (PCR) in 30µl reactions which contained: 
1 x New England Biopeptide (NEB) reaction buffer, 0.2mM dNTPs, 2.5mM MgCl2 (NEB)   
, 0.2µM forward and reverse primers (Iqaba) (Table 2) and thermally cycled in an XP 
PCR machine (Bioer) using the following reaction conditions: 1 cycle at 94ºC for 10 
minutes, 32 cycles at 94ºC for 30 seconds, 52 -63.9ºC for 30 seconds and 72ºC for 5 
minutes. The cell cycle number and MgCl2 concentrations were optimised for each PCR. 
Figure 3.2 are representative gels for control ChIP experiments : Figure 3.2 A & B 
shows that when either no antibody or an anti-IgG was used, no PCR products were 
found which denoted that little or no non-specific precipitation of chromatin occurred.  
Figure 3.2C shows that when primers that extend a 5kb region downstream from the 
Glut4 promoter that does not incorporate the MEF2 binding site were used in MEF2A 
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ChIPs, no PCR products for formed. This showed us that our protocol was sensitive to 
the MEF2A binding region on the Glut4 gene. Figure3.2D shows that our ChIP assay 
could also detect acetyl H3 at the surrounding the MEF2A binding site on the Glut4 
gene. 
 
Figure 5 : Representative gels for control ChIP experiments 
A: ChIP assays performed on input sample using +ve primers without antibody (with beads only) (lane 1) 
with IgG (lane 3) and with MEF2A antibody (lanes 2 and 4).  B: ChIP results from IP samples using + 
primers and IgG (Lane 1) or MEF2A antibody (Lane 2). ChIP results from IN samples using MEF2A 
antibody and -ve or +ve primers are shown in lanes 3 and 4, respectively. Lanes 5 and 6 are blots 
obtained from ChIP assays using acetyl-H3 antibody and +ve primers. The -ve primers amplify a 315 bp 
region that does not contain the MEF2 binding element. It is located 5kb downstream. 
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3.7. Statistical analysis of data. 
 
Data generated from these experiments were presented as means ± SD. Statistical 
differences between all treatments were determined using a one-way repeated measure 
ANOVA, followed by a Turkey-Kramer post Test, using the GraphPad Instat software. 
Significance was accepted when p < 0.05.  
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CHAPTER FOUR 
 
RESULTS 
 
 
Previously, Mukwevho et al. (101) had shown that caffeine treatment of C2C12 
myotubes upregulated total GLUT4 expression via hyperacetylation of H3 (Lys 9/14) in 
the region surrounding the MEF2 binding domain on the glut4 gene and increased 
MEF2A binding to the Glut4 promoter via CaMK II-dependent mechanisms. The 
purpose of the present study was to determine whether p300 is involved in this 
hyperacetylation. 
 
4.1. Curcumin inhibits caffeine-induced acetylation of histone 3 (Lys 9/14) at the 
MEF2 binding site on the Glut4 gene in a dose-dependent manner. 
 
To determine if p300 is involved in acetylating H3 in the vicinity of the MEF2 binding site 
on the Glut4 gene, we co-treated C2C12 myotubes with 5mM caffeine for two hours and 
two doses of curcumin for seven hours and measured the level of H3 acetylation by 
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ChIP. Figure 4.1 shows that caffeine treatment (Caf) caused a 30 % increase (P<0.001 
vs. Control) in acetylated H3 in the region surrounding the MEF2A binding site on the 
Glut4 gene. This observation is consistent with the report by Mukwevho et al. (101). 
Addition of 25µM curcumin (Caf+Cur25) in the culture medium reduced acetyl H3 level 
by 28% (p <0.001; vs. Caf) whereas 40µM Curcumin (Caf+Cur40) caused a 41% (P< 
0.001; vs. Caf) reduction. As curcumin is a potent inhibitor of p300 HAT activity (8), 
these results indirectly show that p300 plays an important role in the caffeine-induced 
hyperacetylation of H3 (Lys 9/14) at the region surrounding the MEF2 site on the Glut4 
gene. 
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Figure 6 : Curcumin treatment attenuates caffeine-induced hyper-acetylation of histone 
H3 at the MEF2 binding site in the Glut4 gene in a dose-dependent manner. 
C2C12 myotubes were treated with 5mM caffeine for two hours in the presence of 40µM or 25µM 
Curcumin. Cells were then crosslinked and subjected to the ChIP assay using an anti-Acetyl H3 (Lys 
9/14) antibody and appropriate primers (see section 3.3.2). The bar graph represents the ratio of IP 
(Immunopreciptate)/ In (Input) normalised to control. Sample size n=5, *P <0.001 vs. CON, # P <0.001 vs. 
Caffeine.  Data is presented as means ± SD. 
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4.2. Caffeine treatment up-regulates p300 content in C2C12 myotubes. 
 
 The mechanism by which caffeine and curcumin alter p300 action on the Glut4 gene 
has not been studied. To begin these studies, we assessed the total content of p300 in 
myotubes that had been treated with caffeine ± the two doses of curcumin, as before, 
using western blot. We found that 5mM caffeine caused a significant up-regulation in 
p300 content in C2C12 myotubes (p<0.001 vs. Con). To our knowledge this represents 
a novel finding that may provide a mechanism to explain the increase in acetylation of 
histones in the neighbourhood of the MEF2A binding site on the Glut4 gene. Inclusion of 
curcumin in the medium significantly decreased the caffeine-induced up-regulation of 
p300 in a dose dependent manner: Caf+Cur25 caused a 22% decrease in p300 content 
whereas Caf+Cur25 reduced p300 by 43% (p <0.001; vs. Caffeine; n=5)  
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Figure 7 : Curcumin inhibits caffeine-induced increase in total p300 in a dose-
dependent manner. 
C2C12 myotubes were treated with 5mM caffeine for two hours in the presence of 40µM or 25µM 
curcumin for seven hours and analysed post treatment for p300 and total histone H3 by western blot. 
Results are normalised to untreated controls. * vs. Control ( P < 0,001, n=5);  # vs. Caffeine (P < 0.001, 
n=5). Data is presented as means ± SD. 
 
4.3. Caffeine treatment increases total lysine 9 and 14 acetylation of 
histone 3 in C2C12 myotubes. 
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 As the previous experiment showed that caffeine significantly increased total p300 
content in C2C12 myotubes, we were interested in whether this correlated with a global 
increase in acetylated H3. Figure 4.3 shows that caffeine treatment induced a 34 % 
increase in total acetylated H3 (Lys 9/14) when compared to control myotubes (P <0.001; 
vs. Control; n=5). Curcumin treatments decreased caffeine-induced up-regulation of 
global H3 acetylation (Lys 9/14) in a dose-dependent manner as shown in Figure 4.3: 
Caf+Cur 25 decreased total acetylation H3 by 27% (p< 0.001; vs. Caffeine; n=5) and 
Caf+Cur40 by 52% (p<0.01; vs. Caffeine; n=5). 
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Figure 8 : Curcumin abolishes caffeine-induced hyperacetylation of histone H3 in a 
dose dependent manner. 
C2C12 myotubes were treated with 5mM caffeine ± 25µM or 40µM curcumin for two hours and analysed 
post-treatment (7 hours) for total acetyl H3 and H3 by western blot. Representative blots and a bar graph 
are shown. In the graph Acetyl H3/ total H3 are normalized to untreated controls.* P < 0.001 vs. Con; # P 
<0.001 vs. Caffeine; , n=5. Data are presented as means ± SD. 
 
4.4. Curcumin treatment abolishes caffeine-induced increase in MEF2A 
binding to the Glut4 gene. 
 
To determine whether the acetylation level H3 in the region surrounding the MEF2 site 
on the Glut4 gene correlated with MEF2A binding at the MEF2 site, we performed ChIP 
assays using appropriate primers and antibodies on myotubes treated with caffeine ± 
the two doses of curcumin. Figure 4.3 shows that caffeine treatment significantly 
increased MEF2A binding to the Glut4 gene by 48% when compared to control cells 
(p<0.001, n=5). This result is in accordance with Mukwevho et al. (101). The increase in 
bound-MEF2A caused by caffeine was completely abolished by Caf+Cur25.  Caf+Cur40 
further reduced Glut4-bound MEF2A to below control levels. As curcumin degrades 
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p300 and inhibits the HAT domain, the decreased binding observed in these 
experiments may be attributed to diminished acetylation of surrounding histones or  
MEF2 protein directly. 
 
Figure 9: Curcumin treatment decreases caffeine-induced MEF2A binding to the Glut4 
gene. 
C2C12 myotubes were treated with 5mM caffeine for two hours in the presence of 25µM or 40µM 
curcumin. Cells were then cross-linked with formaldehyde 4hours after treatments and analysed by ChIP 
assays using appropriate primers and antibodies. The bar graph represents the ratio of 
Immunoprecipitated DNA (IP))/ Input DNA (IN) normalised to control. n=5, *P <0.001 vs. Con, # P <0.001 
vs. Caf. Data is presented as means ± SD. 
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4.5. Curcumin decreases the caffeine-induced increase in GLUT4 content.  
 
To assess the effects of caffeine ± curcumin on GLUT4 content in C2C12 myotubes 
western blots were performed. Myotubes were treated with 5mM caffeine ± 25µM 
curcumin for  3 hours per day for 5 days. Figure 4.5 shows that caffeine treatment 
resulted in a significant 16% increase in GLUT4 content after 5 days of treatment 
(P<0.05, n=6). This is consistent with Ojuka et al. (110) and Mukwevho et al. (101) who 
showed that caffeine also increased GLUT4 in L6 and C2C12 myotubes, respectively.  
Inclusion of 25 mM Curcumin in the medium abolished the effects of caffeine.  
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Figure 10 : Curcumin decreases caffeine induced upregulation of GLUT4 content in 
C2C12 myotubes. 
C2C12 myotubes were treated with 5mM caffeine for three hours for five days with or without 25µM 
Curcumin and analysed post treatment for GLUT4 levels and α-tubulin by western blot described in 
section 3.2.3. Results are represented normalised to untreated controls with sample size, n=6. 
Represented are respective GLUT4 and alpha tubulin blots and a bar graph depicting GLUT4 levels 
normalised to alpha tubulin levels. * P < 0.05 ; # P <0.001 vs Caffeine. Data are presented as means ± 
SD. 
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CHAPTER FIVE 
DISCUSSION OF RESEARCH FINDINGS AND FUTURE RESEARCH 
 
The aim of this thesis was to determine whether the histone acetyltransferase, p300, is 
involved in acetylating histones in the region surrounding the MEF2A binding site on the 
Glut4 gene in response to caffeine treatment. The Glut4 gene was of particular interest 
in the study because upregulation of its expression might serve as a potential 
therapeutic mechanism for patients suffering from type II diabetes.  
5.1. Summary of main findings. 
 
Previously, studies by Mukwevho et al. (101), showed that caffeine induces 
hyperacetylation of histones in the region surrounding the MEF2 binding domain on the 
Glut4 promoter, with subsequent increases in glut4-bound MEF2A and GLUT4 
expression in C2C12 myotubes. In this present study, we also found that treating 
C2C12 myotubes with 5 mM caffeine for 2 hours increased acetyl H3 in this region of 
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the glut4 gene by ~30%,  Glut4-bound MEF2A by ~50% and GLUT4 content by ~ 22%, 
compared to controls. Furthermore, we have shown that caffeine treatment increased 
total contents of p300 and acetyl histone H3 by 30% and 40%, respectively. To our 
knowledge, this is the first study to show these effects of caffeine in skeletal muscle 
cells. We have also shown for the first time that curcumin decreases all these effects of 
caffeine in a dose-dependent manner (Figures 9-10). As curcumin is reported to be a 
highly specific inhibitor of p300 HAT activity (8; 88), these results imply that p300 is 
involved in acetylating histone H3 globally and also specifically in the region 
surrounding the Glut4 gene, in response to caffeine treatment. These results also imply 
that the content of p300 in C2C12 myotubes influences the binding of MEF2A to the 
Glut4 gene and the expression of GLUT4. 
5.2. Increase in p300 content by caffeine. 
 
 As mentioned above, caffeine treatment increased p300 content rapidly. We observed 
~ 30% increase in p300 4 hours after caffeine treatment. The mechanism by which 
caffeine increases p300 content is not known and requires further research. Nair and 
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co-workers (102; 103) have previously shown that p300 expression may be induced by 
calcium-dependent mechanisms. In one study they infected T cells with the human T-
lymphotropic virus type 1 (HTLV-1), which localised to the endoplasmic reticulum and 
Golgi apparatus and caused a sustained release of calcium; they observed increased 
levels of p300 mRNA and several calcium-regulated genes (102). In a subsequent study 
they showed that treatment of T Jurkat cells for 36 hours with various concentrations of 
ionomycin, a calcium ionophore which increases intracellular Ca2+, caused dose-
dependent increases in p300 mRNA and protein (103). These studies reveal that the 
p300 gene responds to changes in intracellular calcium concentration. Previous studies 
from our group have shown that caffeine, in the concentration used in this study, also 
increases intracellular calcium concentration (110).  Results from the studies by Nair et 
al. (102; 103) suggest that caffeine might have upregulated p300 via a calcium-
dependent mechanism and provide a good starting point for future studies into the role 
of calcium in p300 expression by caffeine.  
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5.3. Global and Glut4 gene histone hyperacetylation by caffeine.  
 
Previous studies have suggested that increased hyperacetylation of histones by 
caffeine might be due to CaMK mediated effects on HDACs (101). Caffeine activates 
CaMK which acts on histone deacetylases (HDACs) to induce HDAC nuclear export 
and increased HAT binding transcriptional factors. However the increase in p300 
content  also induces hyperacetylation.  Wei et al., (153) showed that over-expression 
of p300 in transgenic mice increased HAT activity without changing nuclear HDAC 
content. The hypothesis is also supported by findings from other laboratories who 
showed that total acetyl H3 increases when p300 is over-expressed in the hearts of 
transgenic mice, and targets MEF-dependent genes (146; 153).  In this study, the 
elimination of global and Glut4 histone hyperacetylation when p300 content was 
reduced by curcumin also supports this view point. 
Hyperacetylation of histones could also have been due to CaMK-dependent 
increase in p300 activity since caffeine activates CaMK II. Yaun et al. (162), have 
Un
ive
rsi
ty 
of 
 C
ap
e T
ow
n
86 
shown that p300 is phosphorylated in vitro by CaMK II and this phosphorylation is 
absolutely necessary for the transcriptional activity of hypoxia-inducible factor 1(HIF-1) 
in PC12 cells. Co-transfection of these cells with CaMK II -290 and pGAL4p300 
phosphorylated p300 and activated HIF-1 but administration of KN-93 to inhibit CaMK II 
activity abolished these effects. These results show that p300 phosphorylation by CaMK 
is also important for HIF-1 activity in vivo. Chawla et al. (23) have shown that in neronal 
cells, p300 phosphorylation by CaMK IV is necessary for p300/CBP to mediate its 
transcriptional functions. These studies provide evidence that there are CaMK–
dependent effects on p300 which enhances its transcriptional activity. As caffeine 
activates CaMK via a release of calcium from the sarcoplasmic reticulum (110), is its 
highly possible that there were positive CaMK-dependent effects that are enhancing the 
activity of p300 in our study. Futher experiments using CaMK inhibitors should also be 
performed in conjunction with caffeine to reveal whether CaMK activity contributes to 
p300 function in C2C12 mytotubes. Studies of the effects of CaMK activation on p300 
HAT activity at the MEF2A binding site on the Glut4 gene are needed to give further 
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explanation to the results of this study. In addition to the activation of CaMK II activity in 
C2C12 myotubes, caffeine has also been shown to activate AMP-activated protein 
kinase (AMPK) activity in cells (110). Studies have shown that AMPK can also 
phosphorylate HDAC5 on serine residues that result in nuclear export of HDAC5 and 
promote interactions between MEF2 and p300 (90). Therefore, the results obtained in 
this study are indicative of the sum total of CaMK II and AMPK activity. As the aim of 
this thesis focussed on the HAT functions of p300 and not on the relative contributions 
of each pathway on GLUT4 expression we did not inhibit either pathway. However, it is 
accepted and appreciated that these results are the consequences of the activation of 
both pathways, Further experiments will be conducted to determine the effects of each 
pathway on the expression of GLUT4 through p300 associations with MEF2. These 
experiments were not performed for this thesis, but will be perfomed in upcoming 
publications associated with this thesis. 
5.4. Increase in Glut4-bound MEF2A. 
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Mukwevho et al. (101) showed that caffeine treatment also resulted in a significant 
increase in Glut4-bound MEF2A and a concomitant increase in GLUT4 content in 
C2C12 myotubes. Hyperacetylation of histones at gene promoters results in a 
neutralisation of attraction between positively charged histone tails and the negatively 
charged phosphate molecules of DNA; resulting in chromatin relaxation that  increases 
accessibility to transcription factors (10; 40; 42). Thus, it is reasonable to argue that the 
increases in acetylation of H3 in the vicinity of the MEF2A binding site on the Glut4 
gene augmented MEF2A binding to its cis-element in this region which subsequently 
resulted in an up-regulation of GLUT4 expression. Previous studies have also found 
increased binding of MEF2A to the Glut4 gene and increased mRNA after caffeine 
treatment (101).  
           Increased binding of MEF2 transcription factors to gene promoters may also be 
due to acetylation of MEF2 proteins. p300 acetylates MEF2C on seven highly 
conserved lysine residues present on the MADS box and transactivation domains along 
the protein and results in enhanced binding of the transcription factor to its cis element 
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on muscle creatine kinase (MCK) promoter (4; 83). MEF2A acetylation was not 
measured in our study, thus we are unable to say whether the increase in Glut4-bound 
MEF2A observed in caffeine treatment was also due to increased MEF2A acetylation. 
Further experiments would need to be performed to determine whether there was 
enhanced acetylation of MEF2A in response to caffeine.  
5.5. Use of curcumin as a p300 HAT inhibitor. 
 
To determine if p300 was involved in acetylating histones at the MEF2A binding site on 
the Glut4 gene we used a selective inhibitor of p300 namely curucmin. Curcumin is 
highly specific for p300 HAT activity. Studies by Balasubramanyan et al. (8) and Marcu 
et al. (88) have shown that curcumin bind p300 but not PCAF or GCN5. Curcumin binds 
directly to p300 and results in a conformational change in the protein that results in a 
loss of efficiency for the active sites for both histone and acetyl groups. Curcumin 
inhibits p300 HAT activity by specifically binding the HAT domain of p300 in a sequence 
of reactions called Michael addition reactions (88). Once curcumin is covalently bound 
to p300, it renders the HAT domain incapable of acetylation which subsequently tags 
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p300 for protesome-dependent degradation. Figure 4.2 shows that p300 content was 
indeed decreased in a dose-dependent manner by curcumin and demonstrates that the 
curcumin doses chosen in our study was effective in inhibiting p300 content. The 
changes in p300 content correlates well with changes in global and Glut4 promoter 
acetyl H3  and total acetyl H3 levels; suggesting that alterations in acetylation state was 
mediated by cucurmin effects on p300. Specifically, with regard to GLUT4 expression,  
the data suggests that inhibition of p300 by curcumin decreases the acetylation state of 
histone H3 in the region surrounding the MEF2 binding domain on the Glut4 gene 
(Figure 4.1) to reduce MEF2A binding to its cis element (Figure 4.4) and subsequently 
decreases GLUT4 expression (Figure 4.5).  
As discussed earlier in this thesis, p300 plays diverse roles in eukaryotic gene 
transcription. In addition to its HAT functions, p300 is also a bridging molecule that 
connects transcription factors to the general transcription machinery and acts a scaffold 
that promotes the formation of an enhanceosome at local promoter regions through 
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protein–protein and protein-DNA interactions. All these functions are essential for gene 
expression. 
When curcumin binds the HAT domian of p300 it tags the protein for 
proteosome dependent degradation (88). Thus the binding is sequential in that the 
effects of curcumin on p300 is thought to be two-fold : binding and subsequently 
degradtion of the protein. Thus the question of can curcumin bound p300 still perform its 
transcriptional duties or does curcumin immediately tag it for proteosome dependent 
degradtion arises. Does this mean that the curcumin molecule serves as a impetus or 
biomarker for the proteosome degradation pathway? Or does it means that the cell no 
longer considers p300 a functional protein and therefore recycles its amino acids to 
produce functional, curcumin free p300? An experiment using myotubes treated with 
both MG-132, a proteosome dependant degradation inhibitor, and curcumin may 
indicate to us whether p300 can still perform its function if we assay for total acetylation 
levels and assays such as ChIP, which may reveal whether p300 can still bind its 
respective promoters. Since p300 is a potent HAT, and is vital protein for eukaryotic 
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transcription through its cohort of scaffolding and bridging fuctions to the transcriptional 
apparatus due to its apparent size, the level of p300 in cells are kept at a concentration 
that ensures survival (13; 20; 59). Small discrepancies in its content are thought to be 
deleterious to cells (40), therefore the mechanism by which curcumin induces 
degradation in cells may be a motive by the cell to degrade the protein to its monomeric 
constituents so that biosynthesis of p300 occurs, that is p300 that is unbound to 
curcumin which is fully functional. Thus, curcumin-binding to p300 may be inducing 
degradation indirectly, and even though curcumin is thought to tag the protein for 
degradation, this response may actually be a cell-based initiative to promote survival. 
Therefore the measurement in the responses of acetylation and transcriptional activity 
of cells that are treated with both MG-132 and curcumin will reveal whether curcumin 
bound p300 can still perform its functions when the proteosome degradation pathway is 
blocked which will also demonstrate whether degradation is  actually a side effect of 
curcumin. Or it will reveal whether the use of MG-132 does a disservice to already 
innate cellular mechanism to keep p300 at a fully functional level so that survival is 
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uncompromised.From this we can also determine whether the use of MG-132 serves as 
a curcumin antagonist. These experiments were not in the scope of this thesis but will 
be performed for upcoming publications associated with this thesis. 
Feng et al. (35) have shown that curcumin inhibition of p300 decreases MEF2A 
expression in cardiac myocytes. The decrease in MEF2A may be attributed to the fact 
that Mef2a expression may be regulated by p300 (119) and is also autoregulated. We 
did not measure MEF2 levels in response to curcumin in this study. However, if 
curcumin decreases MEF2A expression in C2C12 myotubes as it does in 
cardiomyocytes (35),  this would also have contributed to the decreased binding of 
MEF2A to the Glut4 gene that was seen in the present study. This possibility further 
underscores the need for exploring more effective inhibitors of p300 HAT activity.        
Finally, as curcumin has diverse effects in cells, there could be other mechanisms by 
which curcumin may influence GLUT4 expression in C2C12 myotubes which we have 
not addressed. Of particular relevance to this study would be curcumin’s effects on 
kinases that regulate GLUT4 expression such as CaMK and AMPK.  Interestingly, 
Un
ive
rsi
ty 
of 
 C
ap
e T
ow
n
94 
curcumin has been shown to inhibit CaMK II expression in mouse hippocampus (145). 
Whether or not this occurs in myotubes is unknown. With respect to AMPK activation, 
curcumin has been shown to activate AMPK potently in hepatoma cells which 
subsequently inhibits gluconeogenesis (64). Although previous studies have shown that 
5 mM caffeine does not activate AMPK (110), the combined use of 5 mM caffeine and 
curcumin on AMPK has not been studied.  
5.6. Summary and conclusion.     
 
In summary, this study provides evidence that p300 is involved in acetylating histone H3 
at the MEF2A binding site on the Glut4 gene. p300 interacts directly with the 
MADS/MEF2 domain of MEF2 transcription factors (130) and possesses a potent HAT 
domain that is capable of acetylating all core histones at multiple lysine residues along 
protruding N-terminal tails (9; 108). It also acetylates MEF2 on seven conserved lysine 
residues along the MADS box and transactivation domains (4; 83). Given these 
properties of p300 and the many interactions it has with MEF2 transcription factors; it is 
quite feasible that p300 is also involved in regulating chromatin structure at the MEF2A 
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binding site on the Glut4 gene in response to other agents that increase GLUT4 such as 
exercise or AMPK. Future studies need to look into all these possibilities. Such studies 
will require genetically modified animals or the identification and development of highly 
specific inhibitors and activators of p300. 
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